BEVERLY, Mass., June 9, 2011 /PRNewswire/ — Enzymatics,
Inc. announced today that the company, whose revenues have doubled
every year since 2007, is forecasting triple the revenue in 2011
over 2010 figures. It is also expanding its corporate offices
and manufacturing facility in Beverly, Massachusetts. The
move is one of several significant milestones for the five
year-old, privately held firm that supplies biological reagents as
well as bio-processing consulting services to the international
scientific and healthcare markets. It also demonstrates that
Massachusetts is no longer just a biotech R&D nursery and is
quickly becoming an international center for biotech
manufacturing.
Enzymatics’ proprietary manufacturing process produces
commercial quantities of enzymes measurably superior in purity and
consistency to those created in small batches for the research
field — but at a much lower cost. The timing couldn’t
be better as national and international bioscience and
pharmaceutical companies rush to create genomic diagnostics and
bio-ceutical drug therapies for mass-market distribution.
Reagents are critical components of these products and in Enzymatics, their
manufacturers have found an ideal partner supplier that can scale
up to meet large production levels while exceeding purity standards
and keeping costs down.
“Our growth and expansion are a great confirmation that we had
the right vision at exactly the right time,” states Enzymatics
Co-Founder and President Chris Benoit. “It’s been an
incredible ride that’s about to get even more exciting as we expand
our presence in larger, international markets.” The company
is currently establishing its first full-service overseas office in
Europe. Enzymatics now supports a full time staff of more than 50
and is actively looking to fill an additional 15 positions.
&#
‘/>”/>
SOURCE